Journal Article

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children

Alina S. Bergshoeff, Pieter L. A. Fraaij, Corrien Verweij, Annemarie M. C. van Rossum, Gwenda Verweel, Nico G. Hartwig, Ronald de Groot and David M. Burger

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 54, issue 6, pages 1152-1154
Published in print December 2004 | ISSN: 0305-7453
Published online December 2004 | e-ISSN: 1460-2091 | DOI:
Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details


Objectives: Zidovudine is often administered every 12 h in HIV-infected children, but so far no pharmacokinetic data are available for the administration of this agent every 12 h. We have evaluated the plasma pharmacokinetics of zidovudine administered every 8 h versus every 12 h in HIV-1-infected children.

Methods: In HIV-1-infected children who switched from zidovudine every 8 h to every 12 h, a pharmacokinetic curve was recorded both before and after the switch. Zidovudine plasma levels were measured by HPLC. Pharmacokinetic parameters were calculated by non-compartmental methods.

Results: Six HIV-1-infected children [median age (range) 7.8 (2.5–13.4) years] were included. In these patients, geometric mean ratios of AUC0–24 and Cmax for zidovudine every 12 h versus every 8 h were not significantly different from 1.0.

Conclusions: The plasma pharmacokinetic parameters of zidovudine taken every 8 h and every 12 h were not significantly different and therefore suggest bioequivalence of these two dose frequencies.

Keywords: pharmacokinetics; paediatrics; pharmacology

Journal Article.  1497 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.